Last update 05 Apr 2025

Shenzhen Immuno Cure Biomedical Co., Ltd.

Private Company | Subsidiary Company|
2020|
Guangdong Sheng, China

Overview

Tags

Infectious Diseases
Neoplasms
Respiratory Diseases
Autologous CAR-T
DNA vaccine
Therapeutic vaccine

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Infectious Diseases2
Immune System Diseases1
Top 5 Drug TypeCount
Autologous CAR-T2
DNA vaccine1
Therapeutic vaccine1
Monoclonal antibody1
Top 5 TargetCount
PD-1(Programmed cell death protein 1)3

Related

4
Drugs associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
ICCOV
Target
PD-1
Mechanism
PD-1 modulators [+1]
Active Org.
Shenzhen Immuno Cure Biomedical Co., Ltd.
Originator Org.
Shenzhen Immuno Cure Biomedical Co., Ltd.
Active Indication
COVID-19
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
Therapeutic DNA for HIV/AIDS (Shenzhen Immuno Cure)
Target-
Mechanism-
Active Org.
Shenzhen Immuno Cure Biomedical Co., Ltd. [+1]
Originator Org.
Shenzhen Immuno Cure Biomedical Co., Ltd.
Active Indication
Acquired Immunodeficiency Syndrome [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
IMC-004
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
Shenzhen Immuno Cure Biomedical Co., Ltd. [+1]
Originator Org.
Shenzhen Immuno Cure Biomedical Co., Ltd.
Active Indication
Neoplasms [+2]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
CTR20223007
/ Active, not recruitingPhase 1
治疗用艾滋病核酸注射液（ICVAX）在ART治疗稳定的HIV/AIDS者的安全性、耐受性和免疫原性I期临床试验
[Translation] Phase I clinical trial of safety, tolerability and immunogenicity of ICVAX in HIV/AIDS patients with stable ART treatment
NCT06253533
/ Active, not recruitingPhase 1
Phase I Clinical Trial on Safety, Tolerability and Immunogenicity of HIV Therapeutic DNA Vaccine (ICVAX) in Clinically Stable HIV Patients Under ART
100 Clinical Results associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
Login to view more data
100 Deals associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shenzhen Immuno Cure Biomedical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
2
2
Phase 1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
ICCOV
 ( PD-1 )		COVID-19
More
Phase 1
Therapeutic DNA for HIV/AIDS (Shenzhen Immuno Cure)
Acquired Immunodeficiency Syndrome
More
Phase 1
IMC-004
 ( PD-1 )		Neoplasms
More
Preclinical
IMC-003
 ( PD-1 )		Mesothelioma
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free